

# Superbugs: Office of Health Economics joins MHRA, BARDA and European Commission at 18th annual Scientific Meeting

*Superbugs and Superdrugs takes place on 16th and 17th March at the Holiday Inn Kensington Forum in London, UK.*

LONDON, ENGLAND, UNITED KINGDOM, February 26, 2016 /EINPresswire.com/ -- SMi Group are delighted to announce a new speaker for the [two day event](#) which will gather a global audience of antimicrobial experts and senior industry thought leaders involved in infectious disease from around the world.

Dr Jorge Mestre-Ferrandiz, Director of Consulting from The Office of Health Economics, will join the speaker line-up at the conference on [Superbugs and Superdrug's](#) taking place on 16th – 17th March 2016, when it returns to London for its 18th annual show.

The presentation entitled, “New Business Models for

Antibiotics: Where are we now?” will discuss current economic challenges and address both on-going and future initiatives.

With a focus on industry collaboration, this year’s event will provide an exclusive spotlight on financial incentives to accelerate clinical success and will include keynotes from the US Federal Agency, BARDA; and from the European Commission’s Scientific Officer, Dr Arjon Van Hengel, Scientific Officer.

“

Antimicrobial resistance is recognized as both a public and biodefense threat...I am looking forward to listening to a majority of the presentations/speakers

*Emergent Biosolutions*

In a recent statement, BARDA’s Project Officer from the Anti-Infectives (AI) Program Division of CBRN Countermeasures, said:

“Upon completion of my presentation, I am expecting that attendees will gain a greater understanding of how BARDA

enters into strategic partnerships with industry to advance the development of promising products to counter the growing global threat of antimicrobial resistance. I am also hoping to convey to the audience BARDA’s commitment to work with both our federal and international partners to develop solutions to address this threat. Lastly, I will provide clear guidance to all parties that may have interest in learning more about BARDA as well as mechanisms to partner with BARDA on the development of new antimicrobial products.”

Those who have confirmed attendance include:



MHRA, ACT Surfaces, Arsanis Biosciences, Auspherix, Blueberry Therapeutics, Cantab Anti-infectives, Cempra Pharmaceuticals, Chemical Biology Ventures, Drugs for Neglected Diseases initiative (DNDi), Emergent BioSolutions, Evotec, F. Hoffmann-La Roche, MGB Biopharma, MHRA, Mutabilis, Neem Biotech, Nemesis bioscience, NeoSome Life Sciences, Northern Antibiotics, Nosopharm, Phico Therapeutics, Public Health England, QuantumDX, Spero Therapeutics, Tiber Creek Partners, TNO Pharma, TranScrip Partners and more...

Both a full preliminary list of attendees and the interview with BARDA, is available to download online in the event "[download center](#)" at <http://www.superbugssuperdrugs.com>

---end ---

18th annual conference: Superbugs & Superdrugs  
16-17 March 2016  
Holiday Inn Kensington Forum, London UK  
<http://www.superbugssuperdrugs.com>

Sponsored by Fidelta Ltd and 7iMed

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri  
SMi Group  
+442078276000  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.